Gail Boudreaux Buys 100,000 Shares of Novavax Inc. (NVAX) Stock
Novavax Inc. (NASDAQ:NVAX) Director Gail Boudreaux acquired 100,000 shares of the stock in a transaction that occurred on Tuesday, September 20th. The stock was acquired at an average cost of $1.45 per share, for a total transaction of $145,000.00. Following the completion of the transaction, the director now directly owns 200,000 shares in the company, valued at approximately $290,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of Novavax Inc. (NASDAQ:NVAX) opened at 2.15 on Friday. The stock’s market capitalization is $582.29 million. The stock has a 50 day moving average price of $6.53 and a 200 day moving average price of $6.13. Novavax Inc. has a 1-year low of $1.16 and a 1-year high of $9.39.
Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.04. The business had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $8.03 million. Novavax had a negative net margin of 1,405.84% and a negative return on equity of 112.45%. The business’s quarterly revenue was down 82.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.08) earnings per share. Equities research analysts anticipate that Novavax Inc. will post ($1.09) EPS for the current year.
Several equities analysts recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Novavax in a research report on Wednesday, July 27th. Zacks Investment Research raised Novavax from a “sell” rating to a “hold” rating in a research report on Saturday, May 28th. Vetr lowered shares of Novavax from a “strong-buy” rating to a “buy” rating and set a $8.02 target price for the company. in a research note on Wednesday, June 29th. FBR & Co decreased their target price on shares of Novavax from $17.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, September 16th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $14.00 target price on shares of Novavax in a research note on Wednesday, June 29th. Seven research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $7.06.
A number of institutional investors have recently modified their holdings of the stock. Amalgamated Bank raised its position in shares of Novavax by 1.1% in the second quarter. Amalgamated Bank now owns 28,525 shares of the biopharmaceutical company’s stock valued at $196,000 after buying an additional 300 shares during the last quarter. Stifel Financial Corp increased its stake in shares of Novavax by 1.9% in the second quarter. Stifel Financial Corp now owns 21,990 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 400 shares during the period. Principal Financial Group Inc. increased its stake in shares of Novavax by 0.9% in the second quarter. Principal Financial Group Inc. now owns 47,560 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 445 shares during the period. IFP Advisors Inc increased its stake in shares of Novavax by 1.7% in the first quarter. IFP Advisors Inc now owns 28,296 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 480 shares during the period. Finally, Prudential Financial Inc. increased its stake in shares of Novavax by 5.7% in the second quarter. Prudential Financial Inc. now owns 27,853 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 1,500 shares during the period. 79.84% of the stock is currently owned by institutional investors.
Novavax Company Profile
Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.